2. Search Result
Search Result
Results for "

folate-receptor-alpha-fr-alpha

" in MedChemExpress (MCE) Product Catalog:

8

Inhibitors & Agonists

3

Peptides

2

Inhibitory Antibodies

6

Recombinant Proteins

1

Antibodies

1

Click Chemistry

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99225
    Mirvetuximab

    M9346A

    		 Antifolate Cancer
    Mirvetuximab (M9346A) is an anti-FOLR1 (folate receptor 1) monoclonal antibody. Mirvetuximab is the antibody moiety of folate receptor alpha (FRα)-targeting ADC (Mirvetuximab soravtansine). Mirvetuximab soravtansine can be used in ovarian and other FRα-positive cancer research .
    Mirvetuximab
  • HY-13615A
    EC-17 disodium salt

    		Fluorescent Dye Cancer
    EC-17 (disodium salt) is a folate receptor alpha (FRα) targeting contrast agent with fluorescent properties in the visible light spectrum. The peak excitation and emission wavelengths of EC-17 are 470/520 nm.
    EC-17 disodium salt
  • HY-P99153
    Farletuzumab

    MORAb-003

    		 Antibiotic Cancer
    Farletuzumab (MORAb-003) is a potent folate receptor-alpha (FRα) inhibitor. Farletuzumab is a humanized monoclonal antibody with high affinity for FRα. Farletuzumab possesses growth-inhibitory functions on cells overexpressing FRα. Farletuzumab can be used in research of cancer .
    Farletuzumab
  • HY-132258A
    Mirvetuximab soravtansine (solution)
    1 Publications Verification

    IMGN853 (solution)

    		 Antibody-Drug Conjugates (ADCs) Antifolate Cancer
    Mirvetuximab soravtansine (IMGN853) solution is an anti-folate receptor α (FRα) antibody drug-conjugate (ADC) consisting of the cytotoxic maytansinoid, DM4, covalently linked to the humanized monoclonal antibody M9346A. Mirvetuximab soravtansine selectively binds to folate receptor 1 (FOLR1). Mirvetuximab soravtansine has an anti-proliferative effect via growth arrest and augmented DNA damage .
    Mirvetuximab soravtansine (solution)
  • HY-10822
    Idetrexed

    BGC 945; ONX-0801

    		 Thymidylate Synthase Others
    Idetrexed is a thymidylate synthase inhibitor specifically transported into alpha-folate receptor (alpha-FR)-overexpressing tumors. BGC 945 inhibited thymidylate synthase with a Ki of 1.2 nmol/L .
    Idetrexed
  • HY-P10501
    FRα-targeting peptide C7

    		Antifolate Cancer
    FRα-targeting peptide C7 is a selective peptide ligand for folate receptor α (FRα) that has specific binding to FRα expressing cells and in vivo tumor targeting ability. FRα-targeting peptide C7 can be used in the research of tumor diagnosis and treatment .
    FRα-targeting peptide C7
  • HY-P10501A
    FRα-targeting peptide C7 TFA

    		Antifolate Cancer
    FRα-targeting peptide C7 (TFA) is a selective peptide ligand for folate receptor α (FRα) that has specific binding to FRα expressing cells and in vivo tumor targeting ability. FRα-targeting peptide C7 (TFA) can be used in the research of tumor diagnosis and treatment .
    FRα-targeting peptide C7 TFA
  • HY-P10762
    CBP-1008

    LDC 10B

    		 Peptide-Drug Conjugates (PDCs) Folate Receptor (FR) TRP Channel Cancer
    CBP-1008 is a dual-ligand peptide-drug conjugate (PDC) conjugated to MMAE (HY-15162), targeting Folate receptor α (FRα) and TRPV6. CBP-1008 binds to FRα with high affinity and TRPV6 with low affinity. CBP-1008 has antitumor activity, and can be used in advanced solid tumor research (eg: colorectal cancer, breast cancer, non-small cell lung cancer, ovarian cancer, adrenocortical carcinoma and follicular dendritic cell sarcoma) .
    CBP-1008

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: